168 filings
Page 3 of 9
8-K
x8b76scpkhndt
2 Apr 21
Other Events
5:00pm
8-K
22ojd6ef
29 Mar 21
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:01pm
8-K
h8kb2r upnlopg2r
29 Mar 21
Regulation FD Disclosure
9:18am
8-K
t4p 4eqkubuqao
5 Feb 21
Departure of Directors or Certain Officers
4:24pm
8-K
varekt9nk6i yec
29 Jan 21
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19
7:30am
8-K
l0jhoy v5916
22 Jan 21
Humanigen Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19
10:41am
8-K
f2qhsq1bvmznbucg
19 Jan 21
Other Events
5:24pm
8-K
h3a1bf
14 Jan 21
Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19
4:30pm
8-K
5xkt dxlmm
11 Jan 21
Regulation FD Disclosure
6:07am
8-K
ll4xb97
7 Jan 21
Departure of Directors or Certain Officers
4:30pm
8-K
0pr klx4qz
31 Dec 20
Other Events
4:37pm
8-K
b4s4zu4s
12 Nov 20
Results of Operations and Financial Condition
6:06am
8-K
xdkq5 8jg51n8wv
6 Nov 20
Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to Develop Lenzilumab for COVID-19
9:05am
8-K
gi5a0 x53o42z
4 Nov 20
Humanigen Executes Licensing Agreement for Lenzilumabâ„¢ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines
4:45pm
8-K
8plwr091g
7 Oct 20
Departure of Directors or Certain Officers
4:15pm
8-K
o15f qbef
21 Sep 20
Other Events
8:26am
8-K
q3qawyei msh
11 Sep 20
Departure of Directors or Certain Officers
4:43pm
8-K
2a3lkmkuoag8 t7
4 Sep 20
Other Events
4:36pm
8-K
03r05a83v1xjy
10 Aug 20
Regulation FD Disclosure
9:08am
8-K
2oel6jt0usu83ghat3fm
3 Aug 20
Departure of Directors or Certain Officers
8:30am